# Data Extraction Form adapted from the Cochrane Collaboration

<u>Title of the systematic review:</u> The impact of clinical registries on quality of patient care and health outcomes

Trial Registration no: CRD42015017319

This form has been developed by adopting and customizing the "Data collection form for intervention review — RCTs and non-RCTs" of The Cochrane Collaboration. Some new sections have been added into this tool and the irrelevant sections have been removed from the original form. Information included on this form should be comprehensive, and may be used in the text of the review.

#### Notes on using this data extraction form:

- Be consistent in the order and style you use to describe the information for each included study
- Record any missing information as unclear or not described, to make it clear that the information
  was not found in the study report(s), not that you forgot to extract it.
- Include any instructions and decision rules on the data collection form, or in an accompanying document. It is important to practice using the form and give training to any other authors using the form.
- You will need to protect the document in order to use the form fields (Tools / Protect document)

Title of the paper/article/report
<b>Study ID</b> (surname of first author and year first full report of study was published e.g. Smith 2001)
Report IDs of other reports of this study (e.g. duplicate publications, follow-up studies)
Notes:

#### 1. General Information

1.	Date form completed	
	(dd/mm/yyyy)	
2.	Name/ID of person	
	extracting data	
3.	Report title (title of paper/	
	abstract/report that data	
	are extracted from)	

4.	Report ID (if there are	
	multiple reports of this	
	study)	
5.	Reference details	
6.	Report author contact	
	details	
7.	Publication type (e.g. full	
	report, abstract, letter)	
8.	Study funding source	
	(including role of funders)	
9.	Possible conflicts of interest	
	(for study authors)	
10.	Notes:	

# 2. Eligibility

Study Characteristics	Review Inclusion Criteria (Insert inclusion criteria	Location in text (pg
	for each characteristic as defined in the Protocol)	& ¶/fig/table)
11. Type of study		
12. Participants		
13. Types of Registry		
Describe either a		
clinical registry or a		
CQR which collects		
data on a		
procedure, disease		
or health care		
resource		
14. Collect data		
systematically and		
on ongoing basis		
from the		
population being		
investigated		
15. Types of outcome		
measures		
(mortality/survival,		
measures outcome		
that reflects a		
process or outcome		
of health care		
utilization or cost)		
16. Is registry used as		
an intervention		
(based on inclusion		

Study Characteristics	Review Inclusion Criteria (Insert inclusion criteria	Location in text (pg
	for each characteristic as defined in the Protocol)	& ¶/fig/table)
and exclusion		
criteria in table -1)		
17. <b>Decision</b> (with		
reasons for		
either		
inclusion or		
exclusion)		
18. Notes:		

DO NOT PROCEED IF STUDY IS EXCLUDED FROM REVIEW

# 3. Population and setting

	<b>Description</b> [include comparative information for each group (i.e. intervention and controls) if available]	Location in text (pg & ¶/fig/table)
19. Population description (from which study participants are drawn)		
20. Setting (including location and social context)		
21. Inclusion criteria		
22. Exclusion criteria		
23. Method/s of recruitment of participants		
24. Notes:		

#### 4. Methods

	Descriptions as stated in report/paper	Location in text (pg & ¶/fig/table)
25. Aim of study		
26. <b>Design</b> (e.g. RCT, comparative study with concurrent controls i,e non- randomised, experimental trial, cohort study, case- control study, interrupted time series with a control group or a comparative study without concurrent controls)		

27. Study start date	
28. Study End date	
29. Duration of	
participation	
(from recruitment	
to last follow-up)	
30. Notes:	

## 5. Participants

Provide overall data and, if available, comparative data for each intervention or comparison group.

	Description as stated in report/paper	Location in text
		(pg & ¶/fig/table)
31. Total no.		
participants		
32. Clusters (if		
applicable, no.,		
type, no. people		
per cluster)		
33. Baseline		
imbalances		
34. Withdrawals		
and exclusions		
(if not provided		
below by		
outcome)		
35. <b>Age</b>		
36. <b>Sex</b>		
37. Race/Ethnicity		
38. Severity of		
illness		
39. Co-morbidities		
40. Other treatment		
received		
(additional to		
study		
intervention)		
41. Other relevant		
socio-		
demographics		

	Description as stated in report/paper	Location in text
		(pg & ¶/fig/table)
42. Notes:		

#### 6. Outcomes

	Description as stated in report/paper	Location in text
		(pg & ¶/fig/table)
43. Process outcomes		
44. Patient reported outcomes		

Copy and paste table for each outcome.

#### Outcome 1

	Description as stated in report/paper	Location in text
		¶/fig/table)
45. Outcome name		
46. Time points		
measured (specify		
whether from start		
or end of		
intervention)		
47. Time points reported		
48. Outcome definition		
49. Unit of measurement		
(if relevant)		
50. Scales: upper and		
lower limits (indicate		
whether high or low		
score is good)		
51. Is outcome/tool		
validated?		
(Yes/No/Unclear/Not		
mentioned)		
52. Assumed risk		
estimate (e.g.		
baseline or		
population risk noted		
in Background)		
53. Notes:		

# 7. Information describing registry as intervention

	Description as stated in report/paper	Location in text (pg & ¶/fig/table)
54. Which type of		
organization hosting		
the registry (University,		
research institute,		
professional		
1		
organization, hospital)		
55. Reference population		
(this could be a group of		
countries, a single country, a state or		
-		
territory)		
56. <b>Coverage</b> (what extent		
the eligible population representative of the		
1		
country)		
57. How data are being collected		
(Computerised, Electronic,		
paper based or web based)		
58. Diseases/conditions		
cover (Diabetic, Stroke,		
Cancer, Surgery etc)		
59. Who are involved in		
the management of		
database ( Doctor,		
nurses, epidemiologist,		
statistician, IT specialist,		
General manager,		
consumer/patients,		
administrative staff,		
data collector, data		
manager)		
60. Source of data and		
whether data is linkage		
with other database		
61. Availability of data		
dictionary		
62. Quality assurance		
mechanism		
63. Involvement of		
professional		
bodies/industries		

## 8. The feedback mechanism and frequency of reporting

	Description as stated in report/paper	Location in text
		(pg & ¶/fig/table)
64. Follow up method		
65. Presence of any audit system		
66. Reporting mechanism		
67. Frequency of reporting		
68. Nature of reporting		
69. To whom feedback mechanism is provided		
(clinicians, hospital, funders,		
government		
departments, industry, patients and consumers)		

## 9. Results and findings

Copy and paste the appropriate table for each outcome, including additional tables for each time point and subgroup as required.

#### For randomised or non-randomised trial - Dichotomous outcome

	Description as stated in report/paper	Location in text
		(pg & ¶/fig/table)
70. Comparison		
71. Outcome		
72. Subgroup		
73. <b>Time point</b> (specify whether from start or end of intervention)		

	Description	Location in text (pg & ¶/fig/table)				
74. Results	Inter	Intervention Comparison				
Note whether:						
Troce Wiletien	No.	No.	No. events	No.		
post-intervention	events	participants		participants		
OR	Cremes	participants		participants		
change from						
baseline						
And whether						
Adjusted OR						
<b></b> Unadjusted						
75. Baseline data	lutou		Come			
75. Daseille uala	inter	vention	Comp	arison		
	No.	No.	No. events	No.		
	events	participants	No. events	participants		
	events	participants		participants		
76. No. missing						
participants and						
reasons						
77. No. participants						
moved from other						
group and reasons						
78. Any other results						
reported						
79. Unit of analysis						
(e.g. by individuals,						
health professional,						
practice, hospital,						
community)						
80. Statistical methods used and						
appropriateness of these methods						
(e.g. adjustment for						
correlation)						
81. Reanalysis						
required? (if yes,	Yes/No/Un	clear				
specify why, e.g.	/:/					
correlation						
adjustment)						
82. Reanalysis						
possible?	Yes/No/Un	clear				

	Description as stated in report/paper	Location in text
		(pg & ¶/fig/table)
83. Reanalysed results		
84. Notes:		

## For randomised or non-randomised trial - Continuous outcome

	Descript	ion as state	d in rep	ort/pape	er		Location in text (pg & ¶/fig/table)
85. Comparison							
86. Outcome							
87. Subgroup							
88. Time point (specify whether from start or end							
89. Post- intervention or change from baseline?							
90. Results	l:	ntervention			Compariso	n	
Note whether: post- intervention OR change from baseline And whether Adjusted ORUnadjusted	Mean	SD (or other variance)	N	Mean	SD (or other variance )	N	
91. Baseline data	Mean	SD (or other variance)	N	Mean	SD (or other variance	n N	

	Description as stated in report/paper		Location in text	
				(pg & ¶/fig/table)
92. No. missing				
participants				
and reasons				
93. <b>No.</b>				
participants				
moved from				
other group				
and reasons				
94. Any other				
results				
reported				
95. Unit of analysis				
(e.g. by				
individuals,				
health professional,				
projessional, practice,				
hospital,				
community)				
96. Statistical				
methods used				
and				
appropriatenes				
s of these				
methods (e.g.				
adjustment for				
correlation)				
97. Reanalysis	•••			
required? (if	Yes/No/Unclea			
yes, specify why)	r			
98. Reanalysis				
possible?	Yes/No/Unclea			
•	r			
	1			
99. Reanalysed				
results				
100. <b>Notes:</b>	L			

## For randomised or non-randomised trial - Other outcome

	Description as stated in report/paper	Location in text (pg & ¶/fig/table)
101. Comparison		

	Description a	s stated in rep	ort/paper		Location in text
	2000.150.01.0		o. 4, pape.		(pg &
					¶/fig/table)
102. Outcome					
103. Subgroup					
104. Time point (specify whether from start or end of intervention)					
105. Type of outcome					
106. Results	Intervention	SD (or other	Control	SD (or	
	result	variance)	result	other	
				variance)	
				,	
	Overall result	S	SE (or other v	ariance)	
			01 (0. 000.		
107. No. participant	Intervention		Control		
					-
108. No. missing					
participants and					
reasons					
109. No. participants					
moved from other					
group and reasons					
110. Any other					
results reported					
111. Unit of analysis					
(e.g. by individuals,					
health professional,					
practice, hospital,					
community)					
112. Statistical					
methods used and					
appropriateness of these methods					
113. Reanalysis					
required? (if yes,	•••				
specify why)					
114. Reanalysis					
possible?					
•	•	1			

	Description as stated in report/paper	Location in text (pg & ¶/fig/table)
115. Reanalysed results		
116. <b>Notes:</b>		

# For controlled before-after study

	Description as stated in report/paper				Location in text
					(pg & ¶/fig/table)
117. Comparison					
118. Outcome					
119. Subgroup					
120. Time point (specify whether from start or end of					
intervention)					
intervention or change from baseline?					
122. Results	Intervention result	SD (or other variance)	Control result	SD (or other variance)	
	Overall results		SE (or other va	ariance)	
123. No. participants	Intervention		Control		
124. No. missing participants and reasons					

	Description as stated in report	t/paper	Location in text (pg & ¶/fig/table)
125. <b>No.</b>			
participants			
moved from			
other group and			
reasons			
126. Any other			
results reported			
127. Unit of			
analysis			
(individuals,			
cluster/ groups or			
body parts)			
128. Statistical			
methods used			
and			
appropriateness			
of these			
methods			
129. <b>Reanalysis</b>			
required?	Yes/No/Unclear		
(specify)			
130. Reanalysis			
possible?	Yes/No/Unclear		
131. Reanalysed	<u> </u>		
results			
132. <b>Notes:</b>			

## For interrupted time series or repeated measures study

	Description as stated in report/paper	Location in text (pg & ¶/fig/table)
133. Comparison		
134. Outcome		
135. Subgroup		
136. Length of time points measured (e.g. days, months)		

	Description as stated in repo	Location in text	
		(pg &	
			¶/fig/table)
			1//Jig/tuble/
Total period			
measured			
137. <b>No.</b>			
participants			
measured			
too No missing			
138. No. missing			
participants and reasons			
139. No. time	140. Pre-intervention	141. <b>Post-</b>	
points	140. Tre-intervention	intervention	
measured		intervention	
142. Mean value			
(with variance			
measure)			
143. Difference in		·	
means (post –			
pre)			
_			
144. Percent			
relative change			
reported by			
authors (with			
variance			
measure)			
146. Unit of			
analysis			
(individuals or			
cluster/			
groups)			
147. Statistical			
methods used			
and			
appropriatenes			
s of these			
methods			
148. Reanalysis			
required?	Yes/No/Unclear		
(specify)			
149. Reanalysis			
possible?	Yes/No/Unclear		
F	respired officient		
			1

				100	•			1 1 1.1			
Ind	imnact of	t clinical	registries ni	n allaliti	/ OT	nationt	care at	nd health	Olitcomes: A	A systematic	reviev.
1110	IIII pact of	. Ciii iiCai	i Cgisti ics Oi	I quant	y Oi	patient	carc ar	na ncaith	i outcomics. <i>i</i>	1 Systematic	ICVICV

	Description as stated in report/paper				Location in text (pg & ¶/fig/table)
150. Individual time point results					
151. Read from figure?	 Yes/No/Unclear				
152. Reanalysed results	Change in level	SE	Change in slope	SE	
153. <b>Notes:</b>	1	ı	1		

#### 10. Discussion

	Description as stated in report/paper	Location in text (pg & ¶/fig/table)
154. Key discussion points (with references in detail)		
155. <b>Notes:</b>		

# 11. Limitation and mitigation strategy

	Description as stated in report/paper	Location in text
		(pg & ¶/fig/table)
156. Limitation		
157. Strategies to		
overcome the limitation		
158. Notes:	<u> </u>	

# 12. Recommendations

Description as stated in report/paper	Location in text
	(pg & ¶/fig/table)
	Description as stated in report/paper

#### 13. Other information

	Description as stated in report/paper	Location in text (pg & ¶/fig/table)
161. Key conclusions of		
study authors		
162. References to other		
relevant studies		
163. Correspondence		
required for further		
study information		
(what and from		
whom)		
164. Further study		
information		
requested (from		
whom, what and		
when)		
165. Correspondence		
received (from whom,		
what and when)		
166. <b>Notes:</b>		